Beijing Scinovo Laboratories Ltd. was established in 2016 and is affiliated with Beijing Sunshine Nohe Drug Research Co., Ltd.(which was successfully listed on the STAR Market of the Shanghai Stock Exchange on June 21, 2021, with the stock code 688621). Scinovo Laboratories is a PK/PD research platform and bioanalysis platform that integrates small molecule drug and biological products analysis and covers the entire pre - clinical to clinical chain. 

        Scinovo Laboratories has bioanalysis laboratories, P2 - level cell laboratories, and PCR laboratories that meet the requirements of GLP and GCP. Relying on the technical advantages of mass spectrometry analysis, immunoassay, cell biology, molecular biology, and pathology platforms, as well as the service advantages of a one - stop central laboratory covering sample collection kit preparation to sample analysis completion, it can provide comprehensive PK/PD research services from tissue level, cell level, protein level to molecular level, and bioanalysis services that meet GLP standards. These services include: pharmacokinetic research, bioanalysis, biomarker research and pharmacodynamic, pathological diagnosis, Pharmacometrics Studies, and central laboratory services. 

      Scinovo Laboratories focuses on solving the challenges encountered by customers in the PK/PD research of innovative drugs and is committed to building an internationally leading bioanalysis platform and PK/PD research platform that integrates chemical innovative drugs and biological products.